title: Combination of plasma tumor necrosis factor receptors signaling proteins, beta-amyloid and apolipoprotein E for the detection of Alzheimer's disease.
abstract: Activation of inflammatory processes has been observed within the brain as well as periphery of subjects with Alzheimer's disease (AD). Among several putative neuroinflammatory mechanisms, the tumor necrosis factor-α (TNF-α) signaling system plays a central role. TNF-α converting enzyme (TACE) does not only cleave pro-TNF-α but also TNF receptors, however, whether the TACE activity and soluble TNF receptors (sTNFRs) were changed in the plasma were not clear. The aim of this study was to determine whether the levels of TACE activity and sTNFRs are sufficiently altered in the plasma of AD patients to be helpful in AD diagnosis. We examined TACE levels in the plasma of 153 patients with AD, 98 patients with amnestic mild cognitive impairment (aMCI), 53 patients with vascular dementia (VaD), and 120 age-matched healthy control subjects, and found TACE activity and sTNFRs were significantly higher in patients with AD and aMCI compared with control subjects (TACE: P<0.001, P<0.01; sTNFR1: P<0.001, P<0.001; sTNFR2: P<0.001, P<0.01, respectively). The TACE activity and sTNFRs levels in VaD patients were significantly higher than the levels observed in AD patients (TACE activity: P<0.001, sTNFR1: P<0.01, sTNFR2: P<0.01). In the plasma of AD patients, the levels of both TACE activity and sTNFRs positively correlated with the levels of Aβ40 and negatively correlated with the ratio of Aβ42/Aβ40. AD patients with at least one copy of the ApoEε4 allele showed higher TACE activity and sTNFR plasma levels compared with patients without the ApoEε4 allele. We then combined the data on plasma TACE activity, sTNFRs, and Aβ with the presence of the APOEε4 allele and found that this biomarker panel exhibited a high sensitivity and specificity for discriminating AD patients from non-demented control subjects and VaD patients.
authors.affiliation: Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China.
authors.forename: Jinbiao
authors.initials: J
authors.lastname: Zhang
authors.forename: Jianping
authors.initials: J
authors.lastname: Jia
authors.forename: Wei
authors.initials: W
authors.lastname: Qin
authors.forename: Shuying
authors.initials: S
authors.lastname: Wang
mesh_terms: D051722:ADAM Proteins / Q000378:metabolism; D000072198:ADAM17 Protein; D000368:Aged; D000544:Alzheimer Disease / Q000097:blood / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000097:blood*; D053327:Apolipoprotein E4 / Q000097:blood* / Q000235:genetics; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003072:Cognition Disorders / Q000097:blood / Q000175:diagnosis; D015140:Dementia, Vascular / Q000097:blood / Q000175:diagnosis; D005260:Female; D006801:Humans; D008297:Male; D009154:Mutation; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood*; D012680:Sensitivity and Specificity; D015398:Signal Transduction
chemical_list: D016229:Amyloid beta-Peptides; D053327:Apolipoprotein E4; D015415:Biomarkers; D018124:Receptors, Tumor Necrosis Factor; D051722:ADAM Proteins; D000072198:ADAM17 Protein; C000606462:ADAM17 protein, human